Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

BACKGROUND: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowe...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-Soffer, Gissette, Pavlyha, Marianna, Ngai, Colleen, Thomas, Tiffany, Holleran, Stephen, Ramakrishnan, Rajasekhar, Karmally, Wahida, Nandakumar, Renu, Fontanez, Nelson, Obunike, Joseph, Marcovina, Santica M., Lichtenstein, Alice H., Matthan, Nirupa R., Matta, James, Maroccia, Magali, Becue, Frederic, Poitiers, Franck, Swanson, Brian, Cowan, Lisa, Sasiela, William J., Surks, Howard K., Ginsberg, Henry N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262523/
https://www.ncbi.nlm.nih.gov/pubmed/27986651
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262523/
https://www.ncbi.nlm.nih.gov/pubmed/27986651
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253

Ejemplares similares